Acadia Pharmaceuticals (ACAD) EPS (Weighted Average and Diluted) (2010 - 2026)
Acadia Pharmaceuticals (ACAD) recorded quarterly EPS (Weighted Average and Diluted) of $0.02 in Q1 2026, down 98.76% quarter-over-quarter from $1.61 in Q4 2025, and down 81.82% on a YoY basis from $0.11 in Q1 2025.
Acadia Pharmaceuticals (ACAD) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 10 years deep, the most recent figure standing at $0.02 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 81.82% year-over-year to $0.02; the TTM figure through Mar 2026 stood at $2.21 (up 61.31% YoY), while the FY2025 annual figure was $2.3, up 69.12% from the prior year.
- EPS (Weighted Average and Diluted) was $0.02 for Q1 2026 at Acadia Pharmaceuticals, down from $1.61 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.61 in Q4 2025 to a low of -$0.7 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.12 across 5 years, with a median of $0.1 in 2024.
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) tumbled 135.29% in 2023, then jumped 1900.0% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.26 in 2022, then surged by 207.69% to $0.28 in 2023, then soared by 207.14% to $0.86 in 2024, then jumped by 87.21% to $1.61 in 2025, then sank by 98.76% to $0.02 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.02 (Q1 2026), $1.61 (Q4 2025), and $0.42 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Acadia Pharmaceuticals | 3.68 Bn | 2.83 Bn | 243.27 Mn | 0.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.02 |
| Dec 31, 2025 | 1.61 |
| Sep 30, 2025 | 0.42 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.11 |
| Dec 31, 2024 | 0.86 |
| Sep 30, 2024 | 0.20 |
| Jun 30, 2024 | 0.20 |
| Mar 31, 2024 | 0.10 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | -0.40 |
| Jun 30, 2023 | 0.01 |
| Mar 31, 2023 | -0.27 |
| Dec 31, 2022 | -0.26 |
| Sep 30, 2022 | -0.17 |
| Jun 30, 2022 | -0.21 |
| Mar 31, 2022 | -0.70 |
| Dec 31, 2021 | -0.27 |
| Sep 30, 2021 | -0.09 |
| Jun 30, 2021 | -0.27 |